---
figid: PMC12139130__12964_2025_2275_Fig2_HTML
figtitle: An overview of mechanisms of how gut microbiota increases the efficiency
  of immunotherapies
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12139130
filename: 12964_2025_2275_Fig2_HTML.jpg
figlink: /pmc/articles/PMC12139130/figure/F2/
number: F2
caption: 'An overview of mechanisms of how gut microbiota increases the efficiency
  of immunotherapies. A ICIs. LGG activates cGAS/STING pathway in DCs, promoting CD8+
  T cell and NK cell activation; Inosine binds to A2 AR on T cells, promoting the
  activation of TH1 cells; C. cateniformis reduces the expression of PD-L2 in DCs; B.
  breve and E. hirae share antigenic similarities with tumors, enhancing the cross-reactive
  response of CD8+ T cells. B CAR-T therapy. SCFAs activate mTOR and inhibit the activity
  of deacetylases. C CpG-ODN immunotherapy: CpG-ODN activates the TLR9 receptor on
  myeloid cells, triggering a Th1-type immune response. Gut microbiota binds to the
  TLR4, increasing cytokine production and the efficacy of CpG-ODN immunotherapy. D OVs:
  OVs target tumor cells, promoting ICD. Bifidobacterium have similar antigen with
  tumor cells, triggering the cross-reactive effects. LGG, Lactobacillus rhamnosus GG;
  A2 AR, adenosine A2 A receptor; C. cateniformis, Coprobacillus cateniformis; RGMb,
  repulsive guidance molecule b; B.breve, Bifidobacterium breve; E. hirae,Enterococcus
  hirae; mTOR, mammalian target of rapamycin; TLR, toll-like receptor; OV,oncolytic
  virus; ICD, immunogenic cell death; TAAs, tumor-associated antigens; PAMPs, pathogen-associated
  molecular patterns; DAMPs, damage-associated molecular patterns'
papertitle: Combination strategies of gut microbiota in cancer therapy through metabolic
  reprogramming and immune remodeling
reftext: Lixuan Wang, et al. Cell Commun Signal. 2025;23(NA).
year: '2025'
doi: 10.1186/s12964-025-02275-z
journal_title: 'Cell Communication and Signaling : CCS'
journal_nlm_ta: Cell Commun Signal
publisher_name: BMC
keywords: Gut microbiota | Metabolic reprogramming | Immune remodeling | The TME |
  Polymorphic microbiome | Combination cancer therapy
automl_pathway: 0.9367043
figid_alias: PMC12139130__F2
figtype: Figure
redirect_from: /figures/PMC12139130__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12139130__12964_2025_2275_Fig2_HTML.html
  '@type': Dataset
  description: 'An overview of mechanisms of how gut microbiota increases the efficiency
    of immunotherapies. A ICIs. LGG activates cGAS/STING pathway in DCs, promoting
    CD8+ T cell and NK cell activation; Inosine binds to A2 AR on T cells, promoting
    the activation of TH1 cells; C. cateniformis reduces the expression of PD-L2 in
    DCs; B. breve and E. hirae share antigenic similarities with tumors, enhancing
    the cross-reactive response of CD8+ T cells. B CAR-T therapy. SCFAs activate mTOR
    and inhibit the activity of deacetylases. C CpG-ODN immunotherapy: CpG-ODN activates
    the TLR9 receptor on myeloid cells, triggering a Th1-type immune response. Gut
    microbiota binds to the TLR4, increasing cytokine production and the efficacy
    of CpG-ODN immunotherapy. D OVs: OVs target tumor cells, promoting ICD. Bifidobacterium have
    similar antigen with tumor cells, triggering the cross-reactive effects. LGG,
    Lactobacillus rhamnosus GG; A2 AR, adenosine A2 A receptor; C. cateniformis, Coprobacillus
    cateniformis; RGMb, repulsive guidance molecule b; B.breve, Bifidobacterium breve;
    E. hirae,Enterococcus hirae; mTOR, mammalian target of rapamycin; TLR, toll-like
    receptor; OV,oncolytic virus; ICD, immunogenic cell death; TAAs, tumor-associated
    antigens; PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated
    molecular patterns'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IFNA1
  - AZIN2
  - GADL1
  - IRF7
  - STING1
  - CGAS
  - IFNG
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - CTLA4
  - ADORA2A
  - IL12A
  - IL12B
  - HLA-C
  - CD274
  - PDCD1LG2
  - EMP1
  - RGMB
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD8A
  - CD8B
  - MTUS2
  - MTUS1
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CARTPT
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - MTOR
  - TNF
  - PSMB4
  - TLR4
  - NELFCD
  - TLR9
  - LGG
  - CAMP
  - TMP
  - SCFAs
  - HDACI
  - TNF-a
  - Cancer
---
